Search Result

Results for "

VEGF-A

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Androgen Receptor (2) Apoptosis (5) Autophagy (1) Bacterial (1) Cadherin (1) Caspase (1) Complement System (1) CXCR (1) Dihydroorotate Dehydrogenase (1) DNA/RNA Synthesis (1) Endogenous Metabolite (7) ERK (2) GSK-3 (1) HIF/HIF Prolyl-Hydroxylase (3) HuR (1) Isotope-Labeled Compounds (3) MMP (2) NF-κB (2) p38 MAPK (2) PD-1/PD-L1 (4) PI3K (1) PPAR (2) Ras (1) Reference Standards (3) Small Interfering RNA (siRNA) (3) SRPK (1) STAT (1) Tie (2) VEGFR (34)
By Research Areas:	Cancer (27) Cardiovascular Disease (6) Infection (1) Inflammation/Immunology (14) Metabolic Disease (2) Neurological Disease (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P990148

*Anti-Mouse VEGF-A* Antibody (2G11-2A05)**	VEGFR	Cancer
Anti-Mouse VEGF-A Antibody (2G11-2A05) is a rat-derived anti-VEGF-A IgG2a, κ type antibody inhibitor, binding to mouse *VEGF-A* with high affinity. Anti-Mouse VEGF-A Antibody (2G11-2A05) shows good anti-tumor effect in gastric cancer xenograft models .

HY-P99330

Vanucizumab Anti-Human VEGFA Recombinant Antibody; RO5520985	VEGFR Tie	Cancer
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks *VEGF-A* and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .

HY-101931

hVEGF-IN-1	VEGFR	Cancer
hVEGF-IN-1, a quinazoline derivative, could specifically bind to the G-rich sequence in the internal ribosome entry site A (IRES-A) and destabilize the G-quadruplex structure. hVEGF-IN-1 binds to the IRES-A (WT) with a K_d of 0.928 μM in SPR experiments. hVEGF-IN-1 could hinder tumor cells migration and repress tumor growth by decreasing *VEGF-A* protein expression .

HY-N0545

Taurocholic acid sodium 20+ Cited Publications Sodium taurocholate; N-Choloyltaurine sodium	VEGFR Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-RS22968

Vegfa Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Vegfa Rat Pre-designed siRNA Set A contains three designed siRNAs for Vegfa gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Vegfa Rat Pre-designed siRNA Set A Vegfa Rat Pre-designed siRNA Set A

HY-RS16537

Vegfa Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Vegfa Mouse Pre-designed siRNA Set A contains three designed siRNAs for Vegfa gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Vegfa Mouse Pre-designed siRNA Set A Vegfa Mouse Pre-designed siRNA Set A

HY-RS15635

VEGFA Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
VEGFA Human Pre-designed siRNA Set A contains three designed siRNAs for VEGFA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

VEGFA Human Pre-designed siRNA Set A VEGFA Human Pre-designed siRNA Set A

HY-P991625

VX70	VEGFR	Cancer
VX70 is a humanized monoclonal antibody inhibitor targeting *VEGF-A*. VX70 can be used for cancers research .

HY-128446

CAY10781	VEGFR	Neurological Disease
CAY10781 (Compound 11) is an inhibitor of the neuropilin-1 (NRP-1) and *VEGF-A* interaction. CAY10781 inhibits VEGF-A-induced phosphorylation of VEGFR2 in Catecholamine A-differentiated (CAD) cells ^{[1]< sup>.}

HY-P10550

VGB4	VEGFR	Cancer
VGB4 is a *VEGF-A* and *VEGF-B* antagonist peptide that duplicates two binding domains of *VEGF-B* (loop 1 and loop3) and are linked together by the receptor-binding domain of *VEGF-A* (loop3). VGB4 has significant anti-angiogenic and anti-tumor activities and can regulate tumor growth and metastasis through multiple mechanisms. VGB4 could be used in anti-tumor research .

HY-B1788

Taurocholic acid 20+ Cited Publications N-Choloyltaurine	Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-N0545R

Taurocholic acid sodium (Standard) 5+ Cited Publications Sodium taurocholate (Standard); N-Choloyltaurine sodium (Standard)	Reference Standards VEGFR Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid (sodium) (Standard) is the analytical standard of Taurocholic acid (sodium). This product is intended for research and analytical applications. Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-B1788R

Taurocholic acid (Standard) Taurocholic Acid (Standard)	Reference Standards Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid (Standard) is the analytical standard of Taurocholic acid. This product is intended for research and analytical applications. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-N2187

Deoxyshikonin 2 Publications Verification	Bacterial HIF/HIF Prolyl-Hydroxylase PI3K Apoptosis	Infection Cardiovascular Disease Cancer
Deoxyshikonin increases the expression of *VEGF-C* and *VEGF-A* mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF. Deoxyshikonin inhibited colorectal cancer (CRC) through the PI3K/Akt/mTOR pathway. Deoxyshikonin has proangiogenesis effect and antitumor activity. Deoxyshikonin is an antibacterial agent against methicillin-resistant S. aureus (MRSA) and S. pneumonia (MIC=17 μg/mL) .

HY-10799

EG00229 trifluoroacetate 5+ Cited Publications	Complement System	Cancer
EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC₅₀ of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2 .

HY-P990689

Zifibancimig RO-7250284	VEGFR	Inflammation/Immunology
Zifibancimig is an anti-VEGFA/ANGPT2 IgG1κ monoclonal antibody .

HY-P9906

Bevacizumab Maximum Cited Publications 36 Publications Verification Anti-Human VEGF, Humanized Antibody	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all *VEGF-A* isoforms with high affinity.

HY-P9906A

Bevacizumab (PBS) Maximum Cited Publications 36 Publications Verification Anti-Human VEGF, Humanized Antibody (PBS)	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all *VEGF-A* isoforms with high affinity .

HY-115746

Dimethyl-bisphenol A DMBPA	HIF/HIF Prolyl-Hydroxylase	Cancer
Dimethyl-bisphenol A (DMBPA) is a potent HIF-1α inhibitor. Dimethyl-bisphenol A can decrease Vegfa mRNA expression .

HY-P991418

MW02	VEGFR	Others
MW02 is a human monoclonal antibody (mAb) targeting *VEGFA*. MW02 can be used in Wet age-related macular degeneration research .

HY-P991033

Tovecimig	VEGFR	Inflammation/Immunology
HY-P991033 is an *VEGFA/DLL4*-targeting G1-scFvlh_L-κ type bispecific antibody .

HY-P991097

PM-8002 BNT-327	VEGFR PD-1/PD-L1	Cancer
PM-8002 is a bispecific antibody that targets both PD-L1 and *VEGF-A*. PM-8002 can be used for the study of solid tumors .

HY-P991417

LYN00101	VEGFR	Cancer
LYN00101 is a human monoclonal antibody (mAb) targeting *VEGFA*. LYN00101 can be used in Cervical cancer, Colorectal cancer, Gastric cancer and Ovarian cancer research .

HY-P991416

BAT5906	VEGFR	Others
BAT5906 is a human monoclonal antibody (mAb) targeting *VEGFA*. BAT5906 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .

HY-P99576

Tarcocimab OG1953	VEGFR	Others
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).

HY-N10336

Notoginsenoside R4	VEGFR STAT Akt Ras	Others
Notoginsenoside R4 is a ginsenoside that can be isolated from ginseng roots. In the molecular docking results, Notoginsenoside R4 can target STAT3, AKT1, HRAS, VEGFA and CASP3 .

HY-P990961

Palverafusp alfa IMM-2510; SYN-2510	VEGFR PD-1/PD-L1	Inflammation/Immunology
Palverafusp alfa is an *VEGFA/PDCD1*-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-18333

EG00229	VEGFR	Cancer
EG00229 is an inhibitor for VEGF-A and NRP1 interaction with an IC₅₀ of 8 μM. EG00229 inhibits the migration of HUVECS and the phosphorylation of VEGFR2 in endothelial cells. EG00229 exhibits cytotoxicity in cancer cell A549 .

HY-W653893

Taurocholic acid-d5 sodium	Isotope-Labeled Compounds VEGFR Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid-d₅ (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-W653842

Taurocholic acid-d8 sodium Sodium taurocholate-d₈ (Standard); N-Choloyltaurine-d₈ sodium	Isotope-Labeled Compounds VEGFR Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid-d₈ (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-P99476

ABP 215	VEGFR	Cancer
ABP 215 (Bevacizumab-awwb), a Bevacizumab (Bevacizumab (HY-P9906)) biosimilar, is a humanized IgG1 monoclonal antibody targeting *VEGFA* (VEGFR). ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research .

HY-P3990

Coibamide A	VEGFR Autophagy Apoptosis	Cancer
Coibamide A, an N-methyl-stabilized cytotoxic depsipeptide, shows potent antiproliferative activity. Coibamide A induces autophagosome accumulation via an mTOR-independent mechanism. Coibamide A induces apoptosis. Coibamide A inhibits *VEGFA/VEGFR2* expression and suppresses tumor growth in glioblastoma xenografts .

HY-168560

MMP Inhibitor 4	MMP	Cancer
MMP Inhibitor 4 (compound 4 B) is a potent MMP inhibitor. MMP Inhibitor 4 shows antiproliferative activity. MMP Inhibitor 4 induces cell cycle arrest at subG1 phase. MMP Inhibitor 4 decreases the mRNA expression of MMP2, MMP9 and VEGFA .

HY-B1788S2

Taurocholic acid-d5 Taurocholic Acid-d₅	Isotope-Labeled Compounds Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid-d₅ (Taurocholic Acid-d₅) is deuterium labeled Taurocholic acid. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-P991154

Pumitamig	VEGFR PD-1/PD-L1	Cancer
Pumitamig is a humanized bispecific immunoglobulin (H-γ1-VH_L-κ) dimer antibody targeting human vascular endothelial growth factor A (VEGFA) and human programmed death ligand 1 (PD-L1). Pumitamig is promising for research of various solid tumors .

HY-P9951A

*Ranibizumab (anti-VEGF)* 1 Publications Verification RG-6321 (anti-VEGF)	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-149886

HIF-2α-IN-9	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-9 (compound 35r) is an inhibitor ofHIF-2α. HIF-2α-IN-9 inhibits VEGF-A (IC₅₀=305 nM), and regulates growth-promoting genes in tumor cells, reactivates macrophage-mediated tumor immunity .

HY-163760

ZM-32	HuR MMP	Cancer
ZM-32 is an inhibitor for human antigen R (HuR), that downregulates the expression of VEGF-A and MMP9, and thus inhibits breast cancer tumor angiogenesis. ZM-32 exhibits broad-spectrum anti-proliferative effects in a variety of cancer cell lines, and exhibits antitumor efficacy against MDA-MB-231 in mouse models .

HY-P10831

GNQWFI	VEGFR	Cardiovascular Disease Cancer
GNQWFI, an anti-Flt1 peptide, is a VEGFR1-specific antagonist. GNQWFI blocks the interaction of VEGFR1 with various VEGFR1 ligands, such as VEGFA, VEGFB, and placental growth factor (PIGF) and inhibits VEGF-induced endothelial cell migration and tube formation. GNQWFI is promising for research of cancer, asthma, and other ocular diseases .

HY-P9920A

Ramucirumab (anti-VEGFR)	VEGFR	Cancer
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .

HY-124593

PTC299 3 Publications Verification Emvododstat	VEGFR Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
PTC299 is an orally active inhibitor of VEGFA mRNA translation that selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydroorotate dehydrogenase (DHODH). PTC299 shows good oral bioavailability and lack of off-target kinase inhibition and myelosuppression. PTC299 can be useful for the research of hematologic malignancies .

HY-P3369

Gersizangitide AXT-107	VEGFR Tie Akt	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Gersizangitide (AXT107) is an anti-angiogenic peptide consisting of 20 amino acids, derived from collagen IV. Gersizangitide is an inhibitor of *VEGF-A* and *VEGF-C* and an activator of Tie2. Gersizangitide can block *VEGF* receptor signaling, inhibit vascular leakage, neovascularization and inflammation. Gersizangitide can be used in the research of diseases related to ocular neovascularization and angiogenesis .

HY-117661

SPHINX31 5+ Cited Publications	SRPK VEGFR	Cardiovascular Disease Cancer
SPHINX31 is a potent and selective SRPK1 inhibitor, with an IC₅₀ of 5.9 nM. SPHINX31 inhibits phosphorylation of serine/arginine-rich splicing factor 1 (SRSF1). SPHINX31 also decreases the mRNA expression of pro-angiogenic *VEGF*-A₁₆₅a isoform. SPHINX31 can be used to research neovascular eye disease .

HY-N7043

Isosilybin A 2 Publications Verification	Apoptosis PPAR NF-κB p38 MAPK ERK Androgen Receptor	Inflammation/Immunology Cancer
Isosilybin A is a PPARγ agonist that can be isolated from silymarin. Isosilybin A activates extrinsic and intrinsic pathways of apoptosis through targeting of the Akt-NF-kB-AR axis. Isosilybin A can relieve the inflammatory response in the rosacea model via inhibiting Erk and p38 signaling pathways and M1 macrophage polarization, with its targets related to RELA and VEGFA. Isosilybin A has anti-prostate cancer (PCA) activity ^[1][2][3].

HY-N7043R

Isosilybin A (Standard)	Reference Standards Apoptosis PPAR NF-κB p38 MAPK ERK Androgen Receptor	Inflammation/Immunology Cancer
Isosilybin A (Standard) is the analytical standard of Isosilybin A (HY-N7043). Isosilybin A is a PPARγ agonist that can be isolated from silymarin. Isosilybin A activates extrinsic and intrinsic pathways of apoptosis through targeting of the Akt-NF-kB-AR axis. Isosilybin A can relieve the inflammatory response in the rosacea model via inhibiting Erk and p38 signaling pathways and M1 macrophage polarization, with its targets related to RELA and VEGFA. Isosilybin A has anti-prostate cancer (PCA) activity ^[1][2][3].

HY-P99675

Ivonescimab AK112	PD-1/PD-L1 VEGFR	Cancer
Ivonescimab (AK112) is a *PD-1/VEGF* bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) .

HY-P99116

Faricimab RG7716	VEGFR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .

HY-P10971

Nef-M1	CXCR Apoptosis VEGFR GSK-3 Cadherin Caspase	Cancer
Nef-M1 (Nef-Motif-1) is an antagonist peptide targeting CXCR4 and an apoptosis inducer derived from a myristoylated protein encoded by the nef gene in HIV. Nef-M1 inhibits tumor angiogenesis and epithelial-mesenchymal transition (EMT). Nef-M1 activates the apoptosis pathway by increasing the level of caspase-3 in cancer cells. Nef-M1 simultaneously inhibits *VEGF-A, p-GSK-3β* and vimentin, and enhances E-cadherin, thereby inhibiting angiogenesis and EMT processes. Nef-M1 can be used in the study of colorectal cancer and breast cancer .

Cat. No.	Product Name	Target	Research Area

HY-P10831

GNQWFI	VEGFR	Cardiovascular Disease Cancer
GNQWFI, an anti-Flt1 peptide, is a VEGFR1-specific antagonist. GNQWFI blocks the interaction of VEGFR1 with various VEGFR1 ligands, such as VEGFA, VEGFB, and placental growth factor (PIGF) and inhibits VEGF-induced endothelial cell migration and tube formation. GNQWFI is promising for research of cancer, asthma, and other ocular diseases .

HY-P3369

Gersizangitide AXT-107	VEGFR Tie Akt	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Gersizangitide (AXT107) is an anti-angiogenic peptide consisting of 20 amino acids, derived from collagen IV. Gersizangitide is an inhibitor of *VEGF-A* and *VEGF-C* and an activator of Tie2. Gersizangitide can block *VEGF* receptor signaling, inhibit vascular leakage, neovascularization and inflammation. Gersizangitide can be used in the research of diseases related to ocular neovascularization and angiogenesis .

HY-P10550

VGB4	VEGFR	Cancer
VGB4 is a *VEGF-A* and *VEGF-B* antagonist peptide that duplicates two binding domains of *VEGF-B* (loop 1 and loop3) and are linked together by the receptor-binding domain of *VEGF-A* (loop3). VGB4 has significant anti-angiogenic and anti-tumor activities and can regulate tumor growth and metastasis through multiple mechanisms. VGB4 could be used in anti-tumor research .

HY-P3990

Coibamide A	VEGFR Autophagy Apoptosis	Cancer
Coibamide A, an N-methyl-stabilized cytotoxic depsipeptide, shows potent antiproliferative activity. Coibamide A induces autophagosome accumulation via an mTOR-independent mechanism. Coibamide A induces apoptosis. Coibamide A inhibits *VEGFA/VEGFR2* expression and suppresses tumor growth in glioblastoma xenografts .

HY-P10971

Nef-M1	CXCR Apoptosis VEGFR GSK-3 Cadherin Caspase	Cancer
Nef-M1 (Nef-Motif-1) is an antagonist peptide targeting CXCR4 and an apoptosis inducer derived from a myristoylated protein encoded by the nef gene in HIV. Nef-M1 inhibits tumor angiogenesis and epithelial-mesenchymal transition (EMT). Nef-M1 activates the apoptosis pathway by increasing the level of caspase-3 in cancer cells. Nef-M1 simultaneously inhibits *VEGF-A, p-GSK-3β* and vimentin, and enhances E-cadherin, thereby inhibiting angiogenesis and EMT processes. Nef-M1 can be used in the study of colorectal cancer and breast cancer .

Cat. No.	Product Name	Target	Research Area

HY-P990148

*Anti-Mouse VEGF-A* Antibody (2G11-2A05)**	VEGFR	Cancer
Anti-Mouse VEGF-A Antibody (2G11-2A05) is a rat-derived anti-VEGF-A IgG2a, κ type antibody inhibitor, binding to mouse *VEGF-A* with high affinity. Anti-Mouse VEGF-A Antibody (2G11-2A05) shows good anti-tumor effect in gastric cancer xenograft models .

HY-P99330

Vanucizumab Anti-Human VEGFA Recombinant Antibody; RO5520985	VEGFR Tie	Cancer
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks *VEGF-A* and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .

HY-P990689

Zifibancimig RO-7250284	VEGFR	Inflammation/Immunology
Zifibancimig is an anti-VEGFA/ANGPT2 IgG1κ monoclonal antibody .

HY-P9906

Bevacizumab Maximum Cited Publications 36 Publications Verification Anti-Human VEGF, Humanized Antibody	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all *VEGF-A* isoforms with high affinity.

HY-P9906A

Bevacizumab (PBS) Maximum Cited Publications 36 Publications Verification Anti-Human VEGF, Humanized Antibody (PBS)	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all *VEGF-A* isoforms with high affinity .

HY-P991097

PM-8002 BNT-327	VEGFR PD-1/PD-L1	Cancer
PM-8002 is a bispecific antibody that targets both PD-L1 and *VEGF-A*. PM-8002 can be used for the study of solid tumors .

HY-P991625

VX70	VEGFR	Cancer
VX70 is a humanized monoclonal antibody inhibitor targeting *VEGF-A*. VX70 can be used for cancers research .

HY-P991418

MW02	VEGFR	Others
MW02 is a human monoclonal antibody (mAb) targeting *VEGFA*. MW02 can be used in Wet age-related macular degeneration research .

HY-P991033

Tovecimig	VEGFR	Inflammation/Immunology
HY-P991033 is an *VEGFA/DLL4*-targeting G1-scFvlh_L-κ type bispecific antibody .

HY-P991417

LYN00101	VEGFR	Cancer
LYN00101 is a human monoclonal antibody (mAb) targeting *VEGFA*. LYN00101 can be used in Cervical cancer, Colorectal cancer, Gastric cancer and Ovarian cancer research .

HY-P991416

BAT5906	VEGFR	Others
BAT5906 is a human monoclonal antibody (mAb) targeting *VEGFA*. BAT5906 can be used in Wet age-related macular degeneration and Diabetic macular oedema research .

HY-P99576

Tarcocimab OG1953	VEGFR	Others
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).

HY-P990961

Palverafusp alfa IMM-2510; SYN-2510	VEGFR PD-1/PD-L1	Inflammation/Immunology
Palverafusp alfa is an *VEGFA/PDCD1*-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99476

ABP 215	VEGFR	Cancer
ABP 215 (Bevacizumab-awwb), a Bevacizumab (Bevacizumab (HY-P9906)) biosimilar, is a humanized IgG1 monoclonal antibody targeting *VEGFA* (VEGFR). ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research .

HY-P991154

Pumitamig	VEGFR PD-1/PD-L1	Cancer
Pumitamig is a humanized bispecific immunoglobulin (H-γ1-VH_L-κ) dimer antibody targeting human vascular endothelial growth factor A (VEGFA) and human programmed death ligand 1 (PD-L1). Pumitamig is promising for research of various solid tumors .

HY-P9951A

*Ranibizumab (anti-VEGF)* 1 Publications Verification RG-6321 (anti-VEGF)	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-P9920A

Ramucirumab (anti-VEGFR)	VEGFR	Cancer
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .

HY-P99675

Ivonescimab AK112	PD-1/PD-L1 VEGFR	Cancer
Ivonescimab (AK112) is a *PD-1/VEGF* bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) .

HY-P99116

Faricimab RG7716	VEGFR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .

Recombinant Proteins Recommended:

VEGF-A

Species:	Human (9) Rat (3) Mouse (6) Rabbit (2) Pig (2) Canine (1)
Tag:	His (9) SUMO (1) Tag Free (13) Avi (4)
Source:	HEK293 (9) CHO (1) P. pastoris (3) Sf9 insect cells (2) E. coli (8)

Cat. No.	Compare	Product Name	Species	Source

HY-P72280

	VEGF-A Protein, Pig (His) VEGFA; VEGFVascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF	Pig	E. coli
	The VEGF-A protein is a multifunctional growth factor that is essential for promoting angiogenesis, vasculogenesis, and endothelial cell growth. Its multiple effects include inducing endothelial cell proliferation, promoting migration, inhibiting apoptosis, and increasing vascular permeability. VEGF-A Protein, Pig (His) is the recombinant pig-derived VEGF-A protein, expressed by E. coli , with N-6*His labeled tag.

HY-P73473

	VEGF-A Protein, Canine (HEK293) VEGFA; Vascular endothelial growth factor A; VPF; VEGF	Canine	HEK293
	VEGFA Protein is a vascular endothelial growth factor that is active in angiogenesis and endothelial cell growth. VEGFA Protein induces endothelial cell proliferation, promotes cell migration, inhibits cell apoptosis, and induces vascular permeability. VEGFA Protein consists of 214 amino acids (M1-R214). VEGF-A Protein, Canine (HEK293) is the recombinant canine-derived VEGF-A protein, expressed by HEK293 , with tag free.

HY-P700496

	VEGF-A Protein, Rabbit (His-SUMO) VEGFA; VPF; VEGF; MVCD1; vascular endothelial growth factor A; vascular permeability factor	Rabbit	E. coli
	The VEGF-A protein is a multifunctional growth factor that is essential for promoting angiogenesis, vasculogenesis, and endothelial cell growth. Its multiple effects include inducing endothelial cell proliferation, promoting migration, inhibiting apoptosis, and increasing vascular permeability. VEGF-A Protein, Rabbit (His-SUMO) is the recombinant Rabbit-derived VEGF-A protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.

HY-P700497

	VEGF-A Protein, Rabbit (P. pastoris, His) VEGFA; VPF; VEGF; MVCD1; vascular endothelial growth factor A; vascular permeability factor	Rabbit	P. pastoris
	The VEGF-A protein is a multifunctional growth factor that is essential for promoting angiogenesis, vasculogenesis, and endothelial cell growth. Its multiple effects include inducing endothelial cell proliferation, promoting migration, inhibiting apoptosis, and increasing vascular permeability. VEGF-A Protein, Rabbit (P. pastoris, His) is the recombinant Rabbit-derived VEGF-A protein, expressed by P. pastoris , with N-6*His labeled tag.

HY-P76122

	VEGF164 Protein, Rat (sf9) VEGF-AA; Vascular endothelial growth factor A; Vascular permeability factor; VPF; VEGFA; VEGFA164; VEGF164	Rat	Sf9 insect cells
	The VEGF164 protein is a growth factor critical for vasculogenesis, vasculogenesis, and endothelial cell growth, inducing proliferation, promoting migration, inhibiting apoptosis, and enhancing vascular permeability. It binds to FLT1/VEGFR1, KDR/VEGFR2, heparan sulfate, heparin, NRP1 and DEAR/FBXW7-AS1 receptors. VEGF164 Protein, Rat (sf9) is the recombinant rat-derived VEGF164 protein, expressed by Sf9 insect cells , with tag free.

HY-P70761

	VEGF164 Protein, Mouse (164a.a, P.pastoris) VEGF-AA; Vascular endothelial growth factor A; Vascular permeability factor; VPF; VEGFA; VEGFA164; VEGF164	Mouse	P. pastoris
	VEGF-A Protein is a key member of the VEGF family of cytokines.VEGF-A participates in angiogenesis, vasculogenesis, and endothelial cell growth, inducing endothelial cell proliferation, promoting cell migration, inhibiting cell apoptosis, and inducing vascular permeability.VEGF-A stimulates endothelial cell mitogenesis and cell migration.VEGF164 Protein, Mouse (P.pastoris) is the recombinant mouse-derived VEGF164 protein, expressed by P.pastoris , with tag free.

HY-P70519

	VEGF121 Protein, Human (HEK293, His) VEGF-AA; Vascular endothelial growth factor A; Vascular permeability factor; VPF; VEGFA; VEGF	Human	HEK293
	VEGF121 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF121 Protein, Human (121a.a, HEK293, His) is the recombinant human-derived VEGF121 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of VEGF121 Protein, Human (121a.a, HEK293, His) is 121 a.a., with molecular weight of 16-18 kDa.

HY-P72775

	VEGF120 Protein, Mouse 1 Publications Verification VEGF-AA; Vascular endothelial growth factor A; VPF; VEGFA	Mouse	E. coli
	VEGF-A Protein is a key member of the VEGF family of cytokines.VEGF-A participates in angiogenesis, vasculogenesis, and endothelial cell growth, inducing endothelial cell proliferation, promoting cell migration, inhibiting cell apoptosis, and inducing vascular permeability.VEGF-A stimulates endothelial cell mitogenesis and cell migration.VEGF120 Protein, Mouse is the recombinant mouse-derived VEGF120 protein, expressed by E.coli , with tag free.

HY-P704092

	VEGF206 Protein, Human (His) VEGFA; VEGFVascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF	Human	E. coli
	Vascular Endothelial Growth Factor A (VEGF-A) is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF206 Protein, Human (His) is the recombinant human-derived VEGF206 protein, expressed by E. coli, with N-6*His labeled tag.

HY-P72280AF

	*Animal-Free VEGF* Protein, Pig (His)** VEGFA; VEGFVascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF	Pig	E. coli
	The VEGF-A protein is a multifunctional growth factor that is essential for promoting angiogenesis, vasculogenesis, and endothelial cell growth. Its multiple effects include inducing endothelial cell proliferation, promoting migration, inhibiting apoptosis, and increasing vascular permeability. Animal-Free VEGF Protein, Pig (His) is the recombinant pig-derived animal-FreeVEGF protein, expressed by E. coli , with C-His labeled tag. This product is for cell culture use only.

HY-P703971

	VEGF110 Protein, Human (HEK293) VEGF; VEGFA; L-VEGF; N-VEGF; VPF; MVCD1	Human	HEK293

HY-P7420

	VEGF121 Protein, Human (120 a.a) 2 Publications Verification VEGF-AA; rHuVEGF-121; VPF	Human	E. coli
	VEGF121 Protein, Human (120 a.a), a VEGF isoform splice variant, cannot bind to heparin. VEGF121 Protein is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers.

HY-P7311

	VEGF164 Protein, Rat (CHO) 3 Publications Verification rRtVEGF164; VEGF-AA; VPF	Rat	CHO
	VEGF164 Protein, Rat (CHO) is a potent mediator of angiogenesis and binds the semaphorin receptor, neuropilin1.

HY-P7312

	VEGF164 Protein, Mouse Maximum Cited Publications 6 Publications Verification VEGF-AA; rMuVEGF164; VPF	Mouse	E. coli
	VEGF164 Protein, Mouse is a potent mediator of angiogenesis and binds the semaphorin receptor, neuropilin1.

HY-P78686

	VEGF120 Protein, Mouse (HEK293) RP1-261G23.1; MGC70609; MVCD1; VEGFA; VPF	Mouse	HEK293
	VEGF120 Protein, Mouse (HEK293) is the recombinant mouse-derived VEGF120 protein, expressed by HEK293, with tag free. The total length of VEGF120 Protein, Mouse (HEK293) is 120 a.a., with molecular weight of 18-22 kDa.

HY-P73556

	VEGF145 Protein, Human (HEK293, solution) VEGF-AA; MVCD1; VAS; Vascular endothelial growth factor A; VEGF; VPF	Human	HEK293
	VEGF145 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF145 Protein, Human (HEK293) is the recombinant human-derived VEGF145 protein, expressed by HEK293 , with tag free. The total length of VEGF145 Protein, Human (HEK293) is 145 a.a., with molecular weight of ~16.92 kDa.

HY-P78812

	VEGF120 Protein, Mouse (Biotinylated, His-Avi) RP1-261G23.1; MGC70609; MVCD1; VEGFA; VPF	Mouse	E. coli
	VEGF-A Protein is a key member of the VEGF family of cytokines. VEGF-A participates in angiogenesis, vasculogenesis, and endothelial cell growth, inducing endothelial cell proliferation, promoting cell migration, inhibiting cell apoptosis, and inducing vascular permeability. VEGF-A stimulates endothelial cell mitogenesis and cell migration. VEGF120 Protein, Mouse (Biotinylated, His-Avi) is the recombinant mouse-derived VEGF120 protein, expressed by E. coli , with N-His, N-Avi labeled tag. The total length of VEGF120 Protein, Mouse (Biotinylated, His-Avi) is 120 a.a., with molecular weight of 22-24 kDa.

HY-P73471

	VEGF121 Protein, Human (HEK293) VEGF-AA; MVCD1; VAS; Vascular endothelial growth factor A; VEGF; VPF	Human	HEK293
	VEGF121 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF121 Protein, Human (HEK293) is the recombinant human-derived VEGF121 protein, expressed by HEK293 , with tag free. The total length of VEGF121 Protein, Human (HEK293) is 147 a.a., with molecular weight of ~19.9 & 17.0 kDa, respectively.

HY-P78813

	VEGF165 Protein, Human (Biotinylated, HEK293, Avi) 1 Publications Verification RP1-261G23.1; MGC70609; MVCD1; VEGFA; VPF	Human	HEK293
	VEGF165 is a member of the PDGF/VEGF family encoding a heparin-binding homodimer that is crucial in inducing vascular endothelial cell proliferation and migration during angiogenesis. The VEGF gene is critical for blood vessel development, and its disruption leads to abnormal blood vessel formation in mouse embryos. VEGF165 Protein, Human (Biotinylated, HEK293, Avi) is the recombinant human-derived VEGF165 protein, expressed by HEK293 , with N-Avi labeled tag.

HY-P78814

	VEGF164 Protein, Mouse (Biotinylated, HEK293, His-Avi) RP1-261G23.1; MGC70609; MVCD1; VEGFA; VPF	Mouse	HEK293
	VEGF-A Protein is a key member of the VEGF family of cytokines. VEGF-A participates in angiogenesis, vasculogenesis, and endothelial cell growth, inducing endothelial cell proliferation, promoting cell migration, inhibiting cell apoptosis, and inducing vascular permeability. VEGF-A stimulates endothelial cell mitogenesis and cell migration. VEGF164 Protein, Mouse (Biotinylated, HEK293, His-Avi) is the recombinant mouse-derived VEGF164 protein, expressed by HEK293 , with N-His, N-Avi labeled tag. The total length of VEGF164 Protein, Mouse (Biotinylated, HEK293, His-Avi) is 164 a.a., with molecular weight of 28-33 kDa.

HY-P701279

	*FITC-Labeled VEGF165 Protein, Human (HEK293, His-Avi)* RP1-261G23.1; MGC70609; MVCD1; VEGFA; VPF	Human	HEK293
	VEGF165 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. FITC-Labeled VEGF165 Protein, Human (HEK293, C-His) is the recombinant human-derived FITC-Labeled VEGF165 protein, expressed by HEK293 , with C-His, C-Avi labeled tag. The total length of FITC-Labeled VEGF165 Protein, Human (HEK293, C-His) is 165 a.a., with molecular weight of 27-33 kDa.

HY-P70638

	VEGF164 Protein, Rat (P.pastoris) VEGF-AA; Vascular endothelial growth factor A; Vascular permeability factor; VEGF; VPF	Rat	P. pastoris
	The VEGF164 protein is a growth factor critical for vasculogenesis, vasculogenesis, and endothelial cell growth, inducing proliferation, promoting migration, inhibiting apoptosis, and enhancing vascular permeability. It binds to FLT1/VEGFR1, KDR/VEGFR2, heparan sulfate, heparin, NRP1 and DEAR/FBXW7-AS1 receptors. VEGF164 Protein, Rat (P.pastoris) is the recombinant rat-derived VEGF164 protein, expressed by P. pastoris , with tag free and A36T mutation.

HY-P77279

	VEGF183 Protein, Human (sf9) VEGF-AA; Vascular endothelial growth factor A; Vascular permeability factor; VPF; VEGF	Human	Sf9 insect cells
	VEGF183 Protein is a subtype of Vascular Endothelial Growth Factor A (VEGF-A). VEGF-A is a key member of the VEGF family of cytokines that can promote neovascularization and increase vascular permeability. VEGF183 Protein, Human (sf9) is the recombinant human-derived VEGF183 protein, expressed by Sf9 insect cells , with tag free. The total length of VEGF183 Protein, Human (sf9) is 183 a.a., with molecular weight of ~21 KDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-W653893

Taurocholic acid-d5 sodium
Taurocholic acid-d₅ (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-W653842

Taurocholic acid-d8 sodium
Taurocholic acid-d₈ (sodium) is deuterium labeled Taurocholic acid (sodium). Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-B1788S2

Taurocholic acid-d5
Taurocholic acid-d₅ (Taurocholic Acid-d₅) is deuterium labeled Taurocholic acid. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80929

	VEGFA Antibody (YA013) VEGFA; VEGF; Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF	WB	Human, Mouse, Rat
	VEGFA Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 27 kDa, targeting to VEGFA. It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.

HY-P84117

	VEGFA Antibody (YA3814) VPF; VEGF; MVCD1	WB, ICC/IF, ELISA	Human
	VEGFA Antibody (YA3814) is a mouse-derived and non-conjugated IgG1 antibody, targeting to VEGFA. It can be applicated for WB, ICC/IF, ELISA assays, in the background of human.

HY-P85795

	VEGF-A Antibody (YA5487) VEGFA; VEGF; Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF	WB, ICC/IF, ELISA	Human, Mouse, Rat
	VEGF-A Antibody (YA5487) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to VEGF-A. It can be applicated for WB, ICC/IF, ELISA assays, in the background of human, mouse, rat.

HY-P86376

	VEGF-A Antibody (YA6068) VEGFA; VEGF; Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VPF	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	VEGF-A Antibody (YA6068) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VEGF-A. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.